Rockefeller Capital Management’s Anavex Life Sciences AVXL Stock Holding History

Rockefeller Capital Management’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$55.5K	Buy	18,094 +10,542	+140%	+$45.7K	﹤0.01%	3222
2025 Q4	$26.9K	Buy	7,552 +152	+2%	+$931	﹤0.01%	3369
2025 Q3	$65.9K	Buy	+7,400	New	+$75.1K	﹤0.01%	2774
2023 Q1	–	Sell	-2,700	Closed	-$25K	–	2120
2022 Q4	$25K	Hold	2,700	–	–	﹤0.01%	2708
2022 Q3	$27K	Hold	2,700	–	–	﹤0.01%	2636
2022 Q2	$27K	Hold	2,700	–	–	﹤0.01%	2566
2022 Q1	$33K	Buy	2,700 +1,500	+125%	+$18.4K	﹤0.01%	2494
2021 Q4	$20K	Hold	1,200	–	–	﹤0.01%	2638
2021 Q3	$21K	Buy	1,200 +400	+50%	+$7.96K	﹤0.01%	2555
2021 Q2	$18K	Buy	800 +300	+60%	+$4.44K	﹤0.01%	2518
2021 Q1	$7K	Buy	+500	New	+$5.46K	﹤0.01%	2729

Other funds holding AVXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Rockefeller Capital Management's AVXL Position: Q1 2026 in Review

Rockefeller Capital Management increased its Anavex Life Sciences (AVXL) stake by 140% in Q1 2026, buying an estimated $45.7K and bringing the position to 18,094 shares worth $55.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3222.

Rockefeller Capital Management first reported a position in AVXL in Q1 2021 and has held it in 11 quarters since. The position peaked at $65.9K in Q3 2025. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

Rockefeller Capital Management held 18,094 shares of Anavex Life Sciences worth $55.5K as of Q1 2026.
Rockefeller Capital Management bought 10,542 Anavex Life Sciences shares in Q1 2026, an estimated $45.7K.
Anavex Life Sciences made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3222 holding.
Rockefeller Capital Management first reported a position in Anavex Life Sciences in Q1 2021 and has held it in 11 quarters since.
Rockefeller Capital Management's Anavex Life Sciences position peaked at $65.9K in Q3 2025.
190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.